- Home
- AXSM vs IOVA Comparison
AXSM vs IOVA Comparison
Compare AXSM & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AXSM | IOVA |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 2.1B |
| IPO Year | 2015 | 2008 |
Fundamental Metrics
Financial Performance| Metric | AXSM | IOVA |
|---|---|---|
| Price | $158.03 | $4.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 17 | 10 |
| Target Price | ★ $209.18 | $9.11 |
| AVG Volume (30 Days) | 525.5K | ★ 18.2M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.56 | 14.84 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $58.34 | $49.14 |
| Revenue Next Year | $54.30 | $51.69 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $86.99 | $1.64 |
| 52 Week High | $191.50 | $5.63 |
Technical Indicators
Market Signals| Indicator | AXSM | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 36.68 | 54.36 |
| Support Level | $148.14 | $1.99 |
| Resistance Level | $191.13 | $4.34 |
| Average True Range (ATR) | 4.30 | 0.47 |
| MACD | -1.05 | -0.05 |
| Stochastic Oscillator | 27.13 | 24.18 |
Price Performance
Historical ComparisonAbout AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.